Therefore, in the current research, we devoted to testifying the outcome using G-CSF-primed PBSCs and BM combination grafts in hematological malignancies patients undergoing haplo-HSCT, and compared the results with a contemporary cohort of cases only receiving G-CSF-mobilized PBSCs. Here, CSF3 is linked to hematologic disorder.